Meta-analysis on the association between CYP2D6*10 gene polymorphism and disease free survival of breast cancer patients receiving tamoxifen treatment in Asia

Meta-analysis on the association between CYP2D6*10 gene polymorphism and disease free survival of breast cancer patients receiving tamoxifen treatment in Asia

Literatures about case-control study on the association between CYP2D6*10 gene polymorphism and breast cancer were searched from last updated on May, 2014. Odds ratio of CYP2D6*10 gene distributions in breast cancer patients against healthy control were analyzed. STATA 12 software was applied for in...

Full description

Bibliographic Details
Main Authors:	Zhichen Pu, Xiaolong Yuan, Xuefeng Zhang, Qun Chen, Haitang Xie
Format:	Article
Language:	English
Published:	Bangladesh Pharmacological Society 2014-12-01
Series:	Bangladesh Journal of Pharmacology
Subjects:	Breast cancer Tamoxifen CYP2D6*10 Polymorphism Meta-analysis
Online Access:	https://www.banglajol.info/index.php/BJP/article/view/20849

Similar Items

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
by: Roberta Ferraldeschi, et al.
Published: (2010-04-01)

The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients
by: Wouroud Ismail Al-khalil, et al.
Published: (2022-10-01)

CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study
by: Wickramage I, et al.
Published: (2017-03-01)

Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
by: Charoenchokthavee W, et al.
Published: (2017-04-01)

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
by: Werner Schroth, et al.
Published: (2017-08-01)

Influence of CYP2D6, CYP2C19 and CYP3A5 polymorphisms on plasma levels of tamoxifen metabolites in Algerian women with ER+ breast cancer
by: Amira Boucenna, et al.
Published: (2022-08-01)

CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
by: Jennifer D. Brooks, et al.
Published: (2018-12-01)

Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites
by: Zahra Khalaj, et al.
Published: (2019-05-01)

Physiologically-based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance
by: Kristin eDickschen, et al.
Published: (2012-05-01)

Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen
by: Comfort Ropafadzo Kanji, et al.
Published: (2023-01-01)

Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups
by: Anna Mueller-Schoell, et al.
Published: (2021-05-01)

Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer Impactos do polimorfismo genético do citocromo P450 2D6 (CYP2D6) na terapia com tamoxifeno para câncer de mama
by: Lucas Soares Bezerra, et al.
Published: (2018-12-01)

Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
by: Thomas Helland, et al.
Published: (2017-11-01)

Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis
by: Isabel Blancas, et al.
Published: (2023-06-01)

Distribution of CYP2D6 and CYP2C19 gene polymorphisms in Han and Uygur populations with breast cancer in Xinjiang, China
by: Abudukeremu Muzhapaer, et al.
Published: (2024-04-01)

The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
by: N Fleeman, et al.
Published: (2011-09-01)

Clinical <i>CYP2D6</i> Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy
by: Tessa A. M. Mulder, et al.
Published: (2021-02-01)

Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale
by: Bram C. Agema, et al.
Published: (2023-04-01)

Genetic polymorphism of CYP2D6 gene among Egyptian hypertensive cases
by: Ahmed A.A. Ali, et al.
Published: (2013-08-01)

POLYMORPHISM OF CYTOCHROME P450 2A6 (CYP2A6*1 AND CYP2A6*4) AMONG JAVANESE INDONESIAN SMOKER AND NON SMOKER
by: Christine Patramurti, et al.
Published: (2015-01-01)

Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions
by: Jeiziner C, et al.
Published: (2021-02-01)

Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms
by: Sara S. Reis, et al.
Published: (2019-07-01)

<i>CYP2D6</i> Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients
by: Jemal Hussien Ahmed, et al.
Published: (2019-09-01)

Novel +90G>A Intronic Polymorphism of CYP2D6
by: Monir Modaresi-nejad, et al.
Published: (2015-04-01)

Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer
by: Thomas Helland, et al.
Published: (2021-03-01)

Perspectives of pharmacogenetics approach to personalized tamoxifen therapy
by: M I Savelyeva, et al.
Published: (2017-06-01)

Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites
by: Yuanhuang Chen, et al.
Published: (2021-06-01)

The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major Depression
by: Julian Maciaszek, et al.
Published: (2023-08-01)

CYP2A6 and CYP2E1 polymorphisms in a Brazilian population living in Rio de Janeiro
by: Rossini A., et al.
Published: (2006-01-01)

CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D6∗10 on Interindividual Variation in a Chinese Population
by: Pei Hu, et al.
Published: (2017-05-01)

The prevalence of CYP2D6*10 (100C>T, rs1065852) gene polymorphism in Russian patients with epilepsy (North-Western and Siberian Districts)
by: N. A. Sivakova, et al.
Published: (2019-12-01)

Baihe Zhimu formula attenuates the efficacy of tamoxifen against breast cancer in mice through modulation of CYP450 enzymes
by: Hailong Li, et al.
Published: (2019-09-01)

Allelic and genotype frequencies of major CYP2B6 polymorphisms in the Pakistani population
by: Sagheer Ahmed, et al.
Published: (2021-03-01)

Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population
by: Nada Ezzeldin, et al.
Published: (2018-05-01)

CYP2D6 polymorphisms and their influence on risperidone treatment
by: Puangpetch A, et al.
Published: (2016-12-01)

Which antidepressant agent can be used in patients receiving tamoxifen?
by: A. Maamri, et al.
Published: (2021-04-01)

Genetic polymorphisms of CYP24A1 gene and cancer susceptibility: a meta-analysis including 40640 subjects
by: Yubin Wang, et al.
Published: (2023-09-01)

(TTTA)n polymorphism of CYP19 (aromatase gene) in Euro- and Afro-Brazilians
by: Kátia Kvitko, et al.
Published: (2004-01-01)

The effects of tamoxifen on homocysteine levels in breast cancer patients
by: Eroğlu Aydan, et al.
Published: (2009-12-01)

CYP2D6 Reduced Function Variants and Genotype/Phenotype Translations of CYP2D6 Intermediate Metabolizers: Implications for Personalized Drug Dosing in Psychiatry
by: Espen Molden, et al.
Published: (2021-04-01)